Time to SARS‐CoV‐2 clearance among patients with cancer and COVID‐19

Xu, Wenxin; Piper-Vallillo, Andrew J.; Bindal, Poorva; Wischhusen, Jonathan W.; Patel, Jaymin; Costa, Daniel B.; Peters, Mary Linton B.

doi:10.1002/cam4.3708

Cited by 7 publications

(7 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our group previously published a report of prolonged COVID‐clearance times in oncology patients 7 . Based on these data and Centers for Disease Control and Prevention (CDC) isolation guidelines for patients with moderate to severe immune compromise, 15 during the time of this study from October 2021 to March 2022, our center required two consecutive negative PCR tests prior to return to clinic.…”

Section: Introductionmentioning

confidence: 99%

“…Our group previously published a report of prolonged COVID-clearance times in oncology patients. 7 Based on…”

Section: Introductionmentioning

confidence: 99%

“…The COVID‐19 pandemic has presented a particular challenge in the care of patients with malignancy, as they are at higher risk for severe disease, 1 , 2 , 3 , 4 prolonged viral shedding, 5 , 6 , 7 and diminished humoral response to vaccination 8 , 9 , 10 that is further exacerbated by immunosuppressive cancer‐directed therapies. 11 , 12 COVID infection frequently leads to delays in care and in‐person clinic visits to protect against worsening disease and prevent transmission to other vulnerable patients, and both the American Society of Clinical Oncology (ASCO) and the UK National Institute for Health and Care Excellence (UK‐NICE) recommend pausing or delaying treatment during active infection.…”

Section: Introductionmentioning

confidence: 99%

“…Our group previously published a report of prolonged COVID‐clearance times in oncology patients. 7 Based on these data and Centers for Disease Control and Prevention (CDC) isolation guidelines for patients with moderate to severe immune compromise, 15 during the time of this study from October 2021 to March 2022, our center required two consecutive negative PCR tests prior to return to clinic. However, with rising vaccination rates and evolving viral variants, it is unclear whether this remained the optimal strategy for patients with different cancer subtypes or treatment modalities, and criteria for clearance and resumption of care should be revisited.…”

Section: Introductionmentioning

confidence: 99%

“…13,14 However, there are no clear guidelines for determining clearance and when patients can safely return to clinic.Our group previously published a report of prolonged COVID-clearance times in oncology patients. 7 Based on…”

mentioning

confidence: 99%

See 4 more Smart Citations

Updated COVID‐19 clearance time among patients with cancer in the Delta and Omicron waves

et al. 2023

Self Cite

View full text Add to dashboard Cite

BackgroundCOVID‐19 infection delays therapy and in‐person evaluation for oncology patients, but clinic clearance criteria are not clearly defined.MethodsWe conducted a retrospective review of oncology patients with COVID‐19 at a tertiary care center during the Delta and Omicron waves and compared clearance strategies.ResultsMedian clearance by two consecutive negative tests was 32.0 days (Interquartile Range [IQR] 22.0–42.5, n = 153) and was prolonged in hematologic malignancy versus solid tumors (35.0 days for hematologic malignancy, 27.5 days for solid tumors, p = 0.01) and in patients receiving B‐cell depletion versus other therapies. Median clearance by single negative test was reduced to 23.0 days (IQR 16.0–33.0), with recurrent positive rate 25.4% in hematologic malignancy versus 10.6% in solid tumors (p = 0.02). Clearance by a predefined waiting period required 41 days until an 80% negative rate.ConclusionsCOVID‐19 clearance remains prolonged in oncology patients. Single‐negative test clearance can balance delays in care with risk of infection in patients with solid tumors.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Our group previously published a report of prolonged COVID-clearance times in oncology patients. 7 Based on…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Updated COVID‐19 clearance time among patients with cancer in the Delta and Omicron waves

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

Early Systemic Anti-neoplastic Treatment Post SARS-CoV-2 Infection in Patients with Breast Cancer

Halpern,

Boursi,

Shacham-Shmueli

et al. 2023

Oncol Ther

View full text Add to dashboard Cite

European Respiratory Society statement on long COVID follow-up

et al. 2022

View full text Add to dashboard Cite

Patients diagnosed with COVID-19 associated with SARS-CoV-2 infection frequently experience symptom burden post-acute infection or post-hospitalisation. We aim to identify optimal strategies for follow-up care that may positively impact the patient's quality-of-life (QOL).A European Respiratory Society (ERS) Task Force (TF) convened and prioritised eight clinical questions. A targeted search of the literature defined the time line of long COVID-19 as one to six months post infection and identified clinical evidence in the follow-up of patients. Studies meeting the inclusion criteria report an association of characteristics of acute infection with persistent symptoms, thromboembolic events in the follow-up period and evaluations of pulmonary physiology and imaging. Importantly, this statement reviews QOL consequences, symptom burden, disability and home care follow-up. Overall, the evidence for follow-up care for patients with long COVID-19 is limited.

show abstract

Time to SARS‐CoV‐2 clearance among patients with cancer and COVID‐19

Abstract: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Cited by 7 publications

References 9 publications

Updated COVID‐19 clearance time among patients with cancer in the Delta and Omicron waves

Updated COVID‐19 clearance time among patients with cancer in the Delta and Omicron waves

Early Systemic Anti-neoplastic Treatment Post SARS-CoV-2 Infection in Patients with Breast Cancer

European Respiratory Society statement on long COVID follow-up

Contact Info

Product

Resources

About